Alexander Stafford
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alexander Stafford has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- David J. Mooney
John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, USA
31 shared publications - Kwasi Adu-Berchie
John A. Paulson School of Engineering and Applied Sciences Harvard University Cambridge Massachusetts USA
29 shared publications - Ana Lako
Bristol Myers Squibb, Lawrenceville, New Jersey
28 shared publications - Anita Giobbie-Hurder
Dana-Farber Cancer Institute, Boston, MA
28 shared publications - Charles H. Yoon
Department of Surgical Oncology, Brigham and Women’s Hospital, Harvard Medical School, Boston, USA
28 shared publications - Edward J. Doherty
Attivare Therapeutics Inc
28 shared publications
Latest Publications
- Open Access
- 19 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data S4 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma
Supplementary Figure S4. Vaccine characterization. A-F. Plots showing the distributions of the indicated vaccine parameters for each vaccinated patient (labelled 1 through 23). Scaffold moduli and toughness were only measured beginning at the sixth patient. Modulus refers to the Young’s modulus, which is a measure of the stiffness of the material and its resistance to deformation. Toughness describes the resistance to fracture of a material. Values in A-C represent mean and standard deviation (n = 3), while values in D-F represent single measurement (n = 1).
- 19 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data S4 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma
Supplementary Figure S4. Vaccine characterization. A-F. Plots showing the distributions of the indicated vaccine parameters for each vaccinated patient (labelled 1 through 23). Scaffold moduli and toughness were only measured beginning at the sixth patient. Modulus refers to the Young’s modulus, which is a measure of the stiffness of the material and its resistance to deformation. Toughness describes the resistance to fracture of a material. Values in A-C represent mean and standard deviation (n = 3), while values in D-F represent single measurement (n = 1).
- Open Access
- 19 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma
Supplementary Table 5. Erythema and Induration by Vaccine Administration and Cohort
- 19 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma
Supplementary Table 5. Erythema and Induration by Vaccine Administration and Cohort
- Open Access
- 19 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 6 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma
Supplementary Table 6. Best Overall Response (BOR)
- 19 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 6 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma
Supplementary Table 6. Best Overall Response (BOR)
- Open Access
- 19 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data S6 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma
Supplementary Figure S6. The Z-score normalized expression of markers from the CyTOF panel are shown for the clusters labeled “CD163+ Monoctyes”, “NK Cells”, and “CD4 T Cells”. Markers on the Y-axis are ordered from most to least enriched.
- 19 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data S6 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma
Supplementary Figure S6. The Z-score normalized expression of markers from the CyTOF panel are shown for the clusters labeled “CD163+ Monoctyes”, “NK Cells”, and “CD4 T Cells”. Markers on the Y-axis are ordered from most to least enriched.
- Open Access
- 19 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma
Supplementary Table 2. Adverse Events (possibly related to vaccine)
- 19 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma
Supplementary Table 2. Adverse Events (possibly related to vaccine)
- Open Access
- 19 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data S1 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma
Supplementary Figure S1: Patient Flow Diagram
- 19 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data S1 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma
Supplementary Figure S1: Patient Flow Diagram
- Open Access
- 19 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data S2 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma
Supplementary Figure S2: GM-CSF Microsphere Preparation Using a Double Emulsion Process. The diagram illustrates the step-by-step method for encapsulating GM-CSF within PLGA microspheres.
- 19 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data S2 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma
Supplementary Figure S2: GM-CSF Microsphere Preparation Using a Double Emulsion Process. The diagram illustrates the step-by-step method for encapsulating GM-CSF within PLGA microspheres.
- Open Access
- 19 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 7 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma
Supplementary Table 7. Erythema and Induration by Vaccine Administration and Cohort
- 19 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 7 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma
Supplementary Table 7. Erythema and Induration by Vaccine Administration and Cohort
- Open Access
- 19 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma
Supplementary Table 1. CyTOF panel profiles innate and adaptive immune populations in PBMCs.
- 19 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma
Supplementary Table 1. CyTOF panel profiles innate and adaptive immune populations in PBMCs.
- Open Access
- 19 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data S3 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma
Supplementary Figure S3: Condensation of Oligonucleotide Process.
- 19 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data S3 from First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma
Supplementary Figure S3: Condensation of Oligonucleotide Process.